Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

Small Molecule Combination Therapies Are Being Investigated to Increase Response Rates Researchers agree that now is a crucial time to be involved in hepatitis C virus (HCV) research. “Current ...

Occult HCV and HBV infections are recently identified entities whose existence became evident when nucleic acid amplification assays of enhanced sensitivity were employed for the detection of viral ...

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...